Traws Pharma (FRA:0T20) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0T20 Traws Pharma Inc FRA:0T20
41 GF Score
Price €6.60
GF Value €109.01
! 4 Warning Signs
View Full Analysis

What is Traws Pharma Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Traws Pharma  (FRA:0T20) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Traws Pharma Cyclically Adjusted PS Ratio Related Terms


Traws Pharma Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Traws Pharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Traws Pharma Cyclically Adjusted PS Ratio Chart

Traws Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.03 0.04 0.02 0.00

Traws Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:0T20 vs OSRH, IMNN, XBIO: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Traws Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Cyclically Adjusted PS Ratio falls into.


FRA:0T20
41GF Score
Traws Pharma Inc FRA:0T20
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Traws Pharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Traws Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Traws Pharma's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/333.9520*333.9520
=0.000

Current CPI (Jun. 2026) = 333.9520.

Traws Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1,471.000 241.428 2,034.741
201612 164.000 241.432 226.847
201703 196.000 243.801 268.475
201706 144.000 244.955 196.318
201709 46.000 246.819 62.239
201712 60.500 246.524 81.956
201803 152.333 249.554 203.851
201806 37.727 251.989 49.998
201809 6.867 252.439 9.084
201812 3.467 251.233 4.609
201903 3.750 254.202 4.926
201906 111.813 256.143 145.779
201909 3.563 256.759 4.634
201912 0.091 256.974 0.118
202003 0.110 258.115 0.142
202006 0.111 257.797 0.144
202009 0.116 260.280 0.149
202012 0.095 260.474 0.122
202103 0.080 264.877 0.101
202106 0.074 271.696 0.091
202109 0.075 274.310 0.091
202112 0.060 278.802 0.072
202203 0.061 287.504 0.071
202206 0.065 296.311 0.073
202209 0.069 296.808 0.078
202212 0.063 296.797 0.071
202303 0.062 301.836 0.069
202306 0.063 305.109 0.069
202309 0.063 307.789 0.068
202312 0.061 306.746 0.066
202403 0.062 312.332 0.066
202406 0.052 314.175 0.055
202409 0.053 315.301 0.056
202412 0.015 315.605 0.016
202503 0.007 319.799 0.007
202506 0.407 322.561 0.421
202509 0.000 324.800 0.000
202512 0.000 324.054 0.000
202603 0.000 330.213 0.000
202606 0.000 333.952 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Traws Pharma (FRA:0T20) Overvalued in 2026?

Based on GuruFocus' analysis, Traws Pharma stock appears to be undervalued. The current stock price of €6.60 is trading 93.9% below its estimated GF Value™ of €109.01.

Key valuation signals for FRA:0T20:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €109.01 vs. price of €6.60 (93.9% below fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the FRA:0T20 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Traws Pharma Business Description

Other Exchanges TRAW:USA
Address 12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
41GF Score

Get the complete analysis for FRA:0T20

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.60
Price
€109.01
GF Value